Delivery Order SPE2DB25D3003-SPE2DB25FPWYE
Award Date 8/12/25
Potential Completion Date 8/13/25
Potential Value $43K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $3,418.92. This non-competitive, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- On August 15, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $97,415.40 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $46,237.16. This firm fixed-price delivery order, with an ultimate completion date of July 31, 2025, represents a competitively awarded, non-set-aside procurement executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $53,159.79. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 18, 2025, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication commonly used to treat...
- The Defense Logistics Agency awarded a $14,796.38 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pens. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including moderate-to-severe atopic...
- The Defense Logistics Agency awarded a delivery order valued at $7,827.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other inflammatory...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 22, 2025, for Dupixent 300 mg/2 mL pens with a ceiling value of $14,474.85 under a firm fixed price arrangement. The award, which is not set-aside and competitively awarded, is scheduled for completion by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,291.75 for Dupixent 300 mg/2 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma,...
- The Defense Logistics Agency awarded a $21,060.94 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-competitive, firm fixed price delivery order is expected to be completed by July 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe...